Glenmede Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

Glenmede Trust’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-200	Closed	-$1K	–	2737
2017 Q2	$1K	Hold	200	–	–	﹤0.01%	2577
2017 Q1	$1K	Hold	200	–	–	﹤0.01%	2577
2016 Q4	$1K	Hold	200	–	–	﹤0.01%	2398
2016 Q3	$0	Hold	200	–	–	﹤0.01%	2579
2016 Q2	$0	Hold	200	–	–	﹤0.01%	2551
2016 Q1	$0	Hold	200	–	–	﹤0.01%	2616
2015 Q4	$2K	Hold	200	–	–	﹤0.01%	2446
2015 Q3	$2K	Hold	200	–	–	﹤0.01%	2487
2015 Q2	$2K	Buy	+200	New	+$2.27K	﹤0.01%	2421

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Glenmede Trust's BCRX Position: Q3 2017 in Review

Glenmede Trust sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2017, closing a stake of 200 shares — an estimated $1K sold.

Glenmede Trust first reported a position in BCRX in Q2 2015 and held it in 9 quarters. The position peaked at $2K in Q4 2015. 120 funds tracked by Wall St. Rank hold BCRX as of Q3 2017.

Glenmede Trust reported no remaining BioCryst Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Glenmede Trust sold 200 BioCryst Pharmaceuticals shares in Q3 2017, an estimated $1K.
Glenmede Trust first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 9 quarters.
Glenmede Trust's BioCryst Pharmaceuticals position peaked at $2K in Q4 2015.
120 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2017.

Based on Glenmede Trust's 13F filing for Q3 2017, filed 14 Nov 2017.